Skip to content

Neoliquiritin Cream for Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Trial

Neoliquiritin Cream for Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002136
Enrollment
Unknown
Registered
2025-11-08
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Trial group :Neoliquiritin cream topical application
Control group:Denuded cream topical

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meets the Williams' diagnostic criteria for atopic dermatitis with mild-to-moderate severity (IGA score: 2-3 or EASI score: 0-21); 2. Aged 18 to 70 years regardless of sex; 3. Capable of understanding the study procedures and having provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Other active skin diseases that may affect condition assessment such as contact dermatitis; 2. Systemic treatment with biologics or immunosuppressants within 1 month prior to enrollment; 3. Topical treatments within 14 days including calcineurin inhibitors (tacrolimus or pimecrolimus) corticosteroids PDE-4 inhibitors (crisaborole) JAK inhibitors (ruxolitinib) and topical antihistamines; 4. Severe uncontrolled local or systemic acute/chronic infections; 5. Significant systemic diseases (e.g. cardiovascular respiratory digestive neurological endocrine genitourinary diseases); 6. History of malignancy primary or secondary immunodeficiency or hypersensitivity disorders; 7. Major surgery within 8 weeks before enrollment or planned surgery during the study; 8. Pregnancy lactation or women planning pregnancy; 9. History of alcohol abuse drug addiction or substance abuse; 10. History of severe psychiatric disorders (personal or familial); 11. Participation in other clinical trials within 1 month before enrollment.

Design outcomes

Primary

MeasureTime frame
Eczema Area and Severity Index score (EASI score);

Secondary

MeasureTime frame
Dermatologic Quality of Life Index (DLQI);Itch Intensity Visual Analogue Scale (VAS);Investigator Global Assessment (IGA);

Countries

China

Contacts

Public ContactXiaojie Ding

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai

dingxiaojie1222@163.com18816515830

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026